SUMMARY
The utility of human induced pluripotent stem cells (hiPSCs) is contingent upon genomic integrity and stability. Recurrent genomic aberrations have been observed in human iPSC lines upon long-term culture, ∼10-25% demonstrate karyotype abnormalities. We describe a new and reliable non-integrating episomal plasmid reprogramming method for fresh (unexpanded) peripheral blood mononuclear cells (PBMC) into iPSCs (PBMC-iPSCs). PBMC-iPSCs produced using this method have a superior chromosome-level karyotype stability rate (∼5% abnormality rate for all chromosomes; 2.8% for autosomes). After extended culture PBMC-iPSCs maintain a low rate of abnormalities (2% for autosomes). Deep coverage whole genome sequencing in a subset of PBMC-iPSC lines showed no shared single nucleotide polymorphisms (SNPs) or structural variants are introduced during reprogramming and maintenance of PBMC-iPSCs. iPSCs reprogrammed from unexpanded PBMCs have consistently high cytogenetic stability and minimal genomic aberrations, suggesting this method is highly suited for iPSCs in research and therapeutic clinical applications.
Competing Interest Statement
A US patent US 10,221,395 B2 has been granted describing this novel and efficient method for reprogramming blood to induced pluripotent stem cells. Apart from this issued patent filing the authors have declared that no other competing financial interests exist.
Footnotes
↵† These authors contributed equally.
Supplementary Tables can be viewed at: https://docs.google.com/spreadsheets/d/1rboYasZNdsZ_tgMyhGQlqcxsH8CVBDhK/edit?usp=sharing&ouid=110828706727380725279&rtpof=true&sd=true